4D Molecular Therapeutics (FDMT) Assets Average (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Assets Average data on file, last reported at $539.8 million in Q1 2026.

• On a quarterly basis, Assets Average changed 0.33% year-over-year to $539.8 million in Q1 2026; TTM through Mar 2026 was $539.8 million, a 0.33% change from a year earlier, with the FY2025 full-year figure at $563.5 million, up 25.19% from the prior year.
• Assets Average for Q1 2026 stood at $539.8 million, up from $495.3 million in the prior quarter.
• Over the last five years, Assets Average for FDMT reached as high as $625.0 million in Q2 2024 and fell as low as $252.9 million in Q1 2023.
• Historically, Assets Average has averaged $429.2 million across 5 years, with a median of $448.8 million in 2025.
• Across the five-year window, Assets Average jumped 109.55% in 2024 and dropped 26.67% in 2025, its largest moves.
• Year by year, Assets Average stood at $271.0 million in 2022, then increased by 29.43% to $350.8 million in 2023, then jumped by 65.99% to $582.2 million in 2024, then decreased by 14.92% to $495.3 million in 2025, then grew by 8.98% to $539.8 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $539.8 million in Q1 2026, $495.3 million in Q4 2025, and $448.8 million in Q3 2025.